Company intelligence / Profile preview

TeGenero AG

Würzburg, Bavaria, Germanypmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

TeGenero AG was a German biotech spin-out from the University of Würzburg that developed TGN1412, a humanized monoclonal antibody targeting CD28 as an immunomodulator. In March 2006, its first-in-human Phase I trial resulted in life-threatening cytokine storm reactions among all volunteers. The incident led to global scrutiny of early-phase clinical trials and caused the company's bankruptcy within months. The drug's rights were later acquired by another entity and renamed TAB08 for further development elsewhere.

Therapeutic areas: OncologyImmunology
Modalities: monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

TGN142

Preclinical

Partnerships

Manufacturing partner for TGN1412 was Boehringer Ingelheim during initial development.

Beyond the preview

Go deeper on TeGenero AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TeGenero AG.

Explore the full profile